S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Reasons this Tech Giant is Going Back to Highs
Options Trading Plan–Perfect For Beginners (Ad)
3 Compelling Reasons to Start Buying Undervalued Amazon
5 Reasons Why Amprius is About to Take Flight 
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock market today: Asian shares mixed after interest rates-driven sell-off on Wall Street
Analysts Recommend These Mining Stocks Before Metal Prices Rally
1907, 1929, 1998, 2007--and now 2023? (Ad)
5 Sizzling Tech Companies on the Brink of Bullish Reversals
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Reasons this Tech Giant is Going Back to Highs
Options Trading Plan–Perfect For Beginners (Ad)
3 Compelling Reasons to Start Buying Undervalued Amazon
5 Reasons Why Amprius is About to Take Flight 
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock market today: Asian shares mixed after interest rates-driven sell-off on Wall Street
Analysts Recommend These Mining Stocks Before Metal Prices Rally
1907, 1929, 1998, 2007--and now 2023? (Ad)
5 Sizzling Tech Companies on the Brink of Bullish Reversals
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Reasons this Tech Giant is Going Back to Highs
Options Trading Plan–Perfect For Beginners (Ad)
3 Compelling Reasons to Start Buying Undervalued Amazon
5 Reasons Why Amprius is About to Take Flight 
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock market today: Asian shares mixed after interest rates-driven sell-off on Wall Street
Analysts Recommend These Mining Stocks Before Metal Prices Rally
1907, 1929, 1998, 2007--and now 2023? (Ad)
5 Sizzling Tech Companies on the Brink of Bullish Reversals
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Reasons this Tech Giant is Going Back to Highs
Options Trading Plan–Perfect For Beginners (Ad)
3 Compelling Reasons to Start Buying Undervalued Amazon
5 Reasons Why Amprius is About to Take Flight 
Laser breakthrough could send stock soaring 2,467% (Ad)
Stock market today: Asian shares mixed after interest rates-driven sell-off on Wall Street
Analysts Recommend These Mining Stocks Before Metal Prices Rally
1907, 1929, 1998, 2007--and now 2023? (Ad)
5 Sizzling Tech Companies on the Brink of Bullish Reversals
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
NASDAQ:PRTG

Portage Biotech (PRTG) Stock Forecast, Price & News

$2.55
-0.06 (-2.30%)
(As of 09/21/2023 ET)
Compare
Today's Range
$2.49
$2.59
50-Day Range
$2.35
$3.45
52-Week Range
$2.30
$8.03
Volume
11,017 shs
Average Volume
23,712 shs
Market Capitalization
$45.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.67

Portage Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
396.7% Upside
$12.67 Price Target
Short Interest
Healthy
0.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

221st out of 965 stocks

Crude Petroleum & Natural Gas Industry

45th out of 78 stocks


PRTG stock logo

About Portage Biotech (NASDAQ:PRTG) Stock

Portage Biotech Inc., together with its subsidiaries, research and develops pharmaceutical and biotechnology products. The company's product pipeline includes IMM60, an iNKT cell activator that is in phase I clinical trial; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; TT-4, an adenosine receptor type 2B (A2B) inhibitor to treat solid tumors; TT-53, an A2A/A2B inhibitor to treat solid tumors; TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors; TT-3, an A2B inhibitor to treat colorectal and gastrointestinal cancers; and INT230-6 for the treatment of tumors. It also provides Nanolipogel co-formulation platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products; and STING agonist platform, a proprietary immune priming and boosting technology, offers various ways to target immune stimulation towards the cancer, as well as to co-deliver various signals in a single product. The company is based in Tortola, British Virgin Islands.

PRTG Price History

PRTG Stock News Headlines

Analyst Expectations for Portage Biotech's Future
Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
Portage Biotech in Keytruda Collaboration With Merck
Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
Portage Biotech Inc (PRTG) Receives a Buy from H.C. Wainwright
University Hospitals Portage Medical Center
Why Portage Biotech Stock Is Up Today
Portage Central High School
Portage High School
Track Covid-19 in Portage County, Wisconsin
Portage Biotech Stock (NASDAQ:PRTG), Dividends
Portage Biotech reports FY results
See More Headlines
Receive PRTG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Portage Biotech and its competitors with MarketBeat's FREE daily newsletter.

PRTG Company Calendar

Last Earnings
8/30/2023
Today
9/22/2023
Next Earnings (Estimated)
12/05/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Crude petroleum & natural gas
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRTG
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.67
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+396.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-104,610,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.45 per share

Miscellaneous

Free Float
10,312,000
Market Cap
$45.39 million
Optionable
Not Optionable
Beta
1.31
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Ian B. Walters M.B.A. (Age 55)
    M.D., CEO & Chairman of Board
    Comp: $967.65k
  • Mr. Allan J. Lee Shaw CPA (Age 59)
    Chief Financial Officer
    Comp: $524.08k
  • Mr. Steven Innaimo
    VP of Project Management & Operations
  • Dr. Robert A. Kramer Ph.D.
    Chief Scientific Officer
  • Mr. Brian Wiley (Age 55)
    Chief Bus. Officer
    Comp: $220.69k
  • Mr. Justin Fairchild
    VP of Devel.
  • Mr. Joseph Ciavarella
    Chief Accounting Officer













PRTG Stock - Frequently Asked Questions

Should I buy or sell Portage Biotech stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Portage Biotech in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRTG shares.
View PRTG analyst ratings
or view top-rated stocks.

What is Portage Biotech's stock price forecast for 2023?

3 Wall Street research analysts have issued 1 year price targets for Portage Biotech's stock. Their PRTG share price forecasts range from $9.00 to $18.00. On average, they predict the company's share price to reach $12.67 in the next year. This suggests a possible upside of 396.7% from the stock's current price.
View analysts price targets for PRTG
or view top-rated stocks among Wall Street analysts.

How have PRTG shares performed in 2023?

Portage Biotech's stock was trading at $5.2891 at the start of the year. Since then, PRTG stock has decreased by 51.8% and is now trading at $2.55.
View the best growth stocks for 2023 here
.

Are investors shorting Portage Biotech?

Portage Biotech saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 6,900 shares, a decline of 27.4% from the August 15th total of 9,500 shares. Based on an average trading volume of 12,700 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.1% of the company's stock are sold short.
View Portage Biotech's Short Interest
.

When is Portage Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, December 5th 2023.
View our PRTG earnings forecast
.

How were Portage Biotech's earnings last quarter?

Portage Biotech Inc. (NASDAQ:PRTG) announced its earnings results on Wednesday, August, 30th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.09.

What is Portage Biotech's stock symbol?

Portage Biotech trades on the NASDAQ under the ticker symbol "PRTG."

Who are Portage Biotech's major shareholders?

Portage Biotech's stock is owned by many different retail and institutional investors. Top institutional investors include Bison Wealth LLC (1.20%), Citadel Advisors LLC (0.11%), Ieq Capital LLC (0.09%), Renaissance Technologies LLC (0.06%) and Simplex Trading LLC (0.00%).

How do I buy shares of Portage Biotech?

Shares of PRTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Portage Biotech's stock price today?

One share of PRTG stock can currently be purchased for approximately $2.55.

How much money does Portage Biotech make?

Portage Biotech (NASDAQ:PRTG) has a market capitalization of $45.39 million. The company earns $-104,610,000.00 in net income (profit) each year or ($6.67) on an earnings per share basis.

How can I contact Portage Biotech?

Portage Biotech's mailing address is Craigmuir Chambers Road Town, Tortola D8, VG1110. The official website for the company is www.portagebiotech.com. The company can be reached via phone at 416-929-1806.

This page (NASDAQ:PRTG) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -